Bone News and Research

RSS

Genetics of imatinib resistance in acute lymphoblastic leukemia

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children's Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.

30 Aug 2007

Researchers discover what makes lymphomas tick

University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.

30 Aug 2007

Biologic treatment for rheumatoid arthritis and the risk of cancer

The relationship between rheumatoid arthritis (RA), an autoimmune disease marked by chronic inflammation of the joints and tissue surrounding vital organs, and the incidence of cancer is complicated.

30 Aug 2007

Genial bone advancement trephine effective treatiment for sleep apnea

Sleep disorder and ear, nose and throat specialists at Thomas Jefferson University are examining an innovative procedure to treat obstructive sleep apnea syndrome.

29 Aug 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

29 Aug 2007

New type of male sling procedure to improve the urinary control

Michael Yarborough, a 58-year-old business owner from Waxahachie, Texas, was fortunate. A routine check-up three years ago revealed prostate cancer, but a side effect of his successful surgery was "driving him nuts."

29 Aug 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Secret to bone's strength

Scientists and engineers are eager to understand the secret behind bone's lightweight toughness so they can mimic it in the design of new materials, but previous studies have revealed a number of different strength mechanisms at different scales of focus, rather than a single theory.

28 Aug 2007

IDM Pharma receives not approvable letter for Mifamurtide for treatment of osteosarcoma

IDM Pharma, Inc. ( NASDAQ:IDMI ) announced today that it received a not approvable letter from the U.S. Food and Drug Administration (FDA) after completing the review of the new drug application (NDA) for the investigational drug mifamurtide (L-MTP-PE), formerly known as Junovan, for the treatment of non-metastatic osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

28 Aug 2007

Cervical disc to treat degenerative disease gets FDA green light

The Food and Drug Administration (FDA) in the U.S. has given approval for a cervical disc implant to treat patients with degenerative disc disease.

28 Aug 2007

Calcium for the over-50s prevents broken bones

Australian scientists say people over the age of 50 should take supplements of calcium in order to reduce the risk of bone damage should they fall.

27 Aug 2007

Study looks at large burns

Large burns can trigger cardiac problems and enhanced inflammatory and hypermetabolic responses in patients, a study in the online open access journal Critical Care suggests.

24 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Women ignorant on cholesterol numbers

Adult women are more than twice as likely to know how much they weighed in high school as they are to know their current cholesterol number, and only half of women have had their cholesterol tested in the past year, according to the results of a nationwide survey released today.

22 Aug 2007

High-density diffuse optical tomography helps scan infant brains

Researchers hoping to better understand the development of the infant brain have long been stymied by a formidable obstacle: babies just don't want to sit still for brain scans.

22 Aug 2007

Study finds women more likely to know high school weight than cholesterol numbers

21 Aug 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology.

21 Aug 2007

Pharmion and MethylGene announce orphan drug designation for treatment of Hodgkin's lymphoma

Pharmion Corporation, along with its collaborator MethylGene Inc., today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug for the treatment of Hodgkin's lymphoma in the United States.

21 Aug 2007

Once a year treatment for osteoporosis now available in the U.S.

A once-a-year treatment for the bone-thinning disease osteoporosis has been given approval by the Food and Drug Administration (FDA) in the United States.

20 Aug 2007